New Delhi: All India Institute of Medical Sciences (AIIMS), Delhi, is now planning to being the Paediatric clinical trials of the indigenous Bharat Biotech’s coronavirus vaccine “Covaxin” in few days, sources revealed on Thursday.
The paediatric trials for Covaxin started at AIIMS Patna on June 1 after Bharat Biotech’s coronavirus vaccine received the Drugs Controller General of India (DCGI) approval to being clinical trials on children on May 11.
“AIIMS Patna has started trials in the age of 12-18 years, we have started clinical trials of Covaxin after registration for this age only,” Dr Prabhat Kumar Singh, Director, AIIMS, Patna is quoted as saying by ANI.
“After these trials, the age group will be 6-12 years and then 2-6 years but now we have started trails in the age group of 12-18 years,” he added.
Earlier, VK Paul, Member (Health), Niti Aayog had said, “Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.”
India’s COVID-19 Vaccine Tally
India on Thursday (June 3) crossed the 22 crore figure in vaccination doses across the country according to the date of the Union Ministry of Health and Family Welfare. A total of 22,10,43,693 vaccine doses have been administered till 7 am on June 3. Out the this, 24,26,265 doses were given on June 2 alone.
The liberalised and accelerated phase-3 strategy of COVID-19 vaccination has come into force from May 1, 2021 after which everyone above the age of 18 was eligible to receive a vaccine shot.
Out of the total doses administered on June 2, 21,90,941 were first dose beneficiaries while 2,35,324 were second dose beneficiaries.
Maharashtra was the top state in number 0f vaccinations at 2,30,52,074 (1,84,00,557 first dose and 46,51,517 second dose) followed by Uttar Pradesh at 1,90,34,656 (1,55,01,696 first dose and 35,32,960 second dose) and Rajasthan at 1,72,31,186 (1,40,80,570 first dose and 31,50,616 second dose).